ESC 2020: Novartis’ inclisiran continues to impress with post-hoc analysis

PCSK9 inhibitors have largely been limited to patients who are unable to lower LDL-C levels with conventional lipid-lowering therapies. Credit: Shidlovski / Shutterstock.



  • inclisiran